The Year in Rheumatic Disorders 2001 by J.S. Hill Gaston

By J.S. Hill Gaston

Maintaining up to now with the tremendous volume of released papers in rheumatology is a tough job for the person surgeon. supplying an summary of the present literature, this e-book identifies the papers released long ago eighteen months that experience possibly replaced perform, or that expect (probable) destiny advancements. it's a hugely centred evaluate of the present literature, compiled by way of a professional crew from one of many major facilities within the box. Designed for ease of use, this can be a useful guidebook that each physician treating sufferers with rheumatic problems should still continue inside effortless succeed in.

Show description

Read or Download The Year in Rheumatic Disorders 2001 PDF

Best nonfiction_2 books

Latin Inscriptions, 1896-1926

This presentation of 226 Latin inscriptions chanced on in the course of the early years of excavation at Corinth is split into major sections: Inscriptions of the Republican interval and Inscriptions of the Imperial interval. each one inscribed piece of stone is defined intimately and any readable texts are transcribed and commented on.

Cap'n Fatso

"Walter Mitty in a sailor go well with. " - Admiral Arleigh Burke

Photosystem I

This publication summarizes the advances made within the final decade within the biophysics, biochemistry, and molecular biology of the enzyme referred to as Photosystem I, the light-induced plastocyanin: ferredoxin oxidoreductase. This quantity is a different compilation of chapters that come with info on molecular structure, protein-pigment interactions, excitation and electron move dynamics, protein-cofactor interactions, kinetics of electron move and bioassembly of proteins and cofactors.

Additional info for The Year in Rheumatic Disorders 2001

Example text

Trial was between etanercept (two doses) and methotrexate, whereas the ATTRACT trial compared methotrexate with infliximab plus methotrexate. Concomitant methotrexate with infliximab is warranted because of the immunogenicity of infliximab (which incorporates part of a mouse IgG molecule); methotrexate appears to decrease the formation of antibodies to the chimeric antiTNF antibody. Etanercept, being wholly human (p75—human Fc) does not require this co-treatment. This might explain why some degree of progression of erosion was still measurable in the etanercept group, whereas erosion scores in the ATTRACT study barely progressed over 54 and 102 weeks in the infliximab plus methotrexate group.

How applicable this particular finding is to RA is questionable. Conclusion These findings suggest that anti-TNF treatment not only alters the cytokine profile but affects cellular infiltration, adhesion molecule expression and the Tcell cytokine balance. It also shows that the anti-CD4 treatment’s lack of efficacy is in part attributable to a failure to eliminate CD4+ T cells from the joint and in part due to persistent IFN-γ production by activated T cells. Finally, combination treatment exerts synergistic effects in this particular model.

Etanercept was well tolerated. INTERPRETATION. Etanercept is safe and effective in psoriatic arthritis, and offers patients a new therapeutic option for the control of their disease. Comment Similar encouraging reports have appeared in abstract form on the treatment of psoriatic arthritis with infliximab. Since psoriatic arthritic may on occasion be difficult to treat and resistant to agents which are effective in RA, an additionaltherapeutic option is very welcome. The comparison with placebo, while necessary in assessing treatment, is not the most relevant one for every day practice, and comparison with methotrexate will be valuable.

Download PDF sample

The Year in Rheumatic Disorders 2001 by J.S. Hill Gaston
Rated 4.09 of 5 – based on 17 votes